| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $7.0M | +5.8% | +75.2% |
| SG&A Expense | $1.0M | -1.3% | +9238.5% |
| Operating Income | -$8.0M | -4.9% | — |
| Net Income | -$8.0M | -8.7% | — |
| EPS (Basic) | -$0.25 | -8.7% | — |
| EPS (Diluted) | -$0.25 | -8.7% | — |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $10.4M | +36.1% | — |
| Short-term Investments | $17.4M | -36.9% | — |
| Current Assets | $30.8M | -22.0% | — |
| Total Assets | $33.0M | -16.5% | — |
| Current Liabilities | $7.2M | +11.3% | +5124.5% |
| Total Liabilities | $10.3M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$19.2M | — | — |
| Investing Cash Flow | -$17.3M | — | — |
| Financing Cash Flow | $18.5M | — | — |
| +8.2% |
| +7364.9% |
| Stockholders' Equity | $22.7M | -24.3% | — |